All studies
AuthorisedTherapeutic exploratory (Phase II)Interventional

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of RO7568282 in Participants with Early-Stage Parkinson’s Disease

Parkinson’s disease is a condition that affects movement and worsens over time. This research study looks at an experimental medicine called RO7568282 to see if it can slow down this progression in people who are in the early stages of the condition. Participants will be placed into groups by chance. Some will receive the trial medicine at different doses, while others will receive a dummy treatment called a placebo. Neither the participants nor their doctors will know who gets which treatment. Over roughly two years, the study team will closely monitor changes in movement, general health, and emotional wellbeing. They will also run regular blood tests and heart checks to ensure the medicine is safe. The trial aims to find out if this treatment could offer a new way to help manage Parkinson’s in the future.

At a glance

Status
Authorised
Phase
Therapeutic exploratory (Phase II)
Sponsor
F. Hoffmann-La Roche AG
Enrolment target
299
Start
21 Oct 2026

What is this study about?

Parkinson’s disease is a condition that affects the brain, leading to symptoms like shaking, stiffness, and difficulty with balance and movement. Over time, these symptoms generally become more noticeable. Current treatments help control these symptoms on a daily basis, but they do not stop the underlying condition from gradually progressing.

This clinical trial is testing an experimental medicine named RO7568282. Scientists hope that this medicine might help protect brain cells and slow down the worsening of movement problems. Because the medicine is still being developed, it needs to be carefully tested in humans to see if it works and whether it is safe.

The trial is designed as a 'double-blind, placebo-controlled' study. This means some participants will take the study drug, while others will take an inactive dummy medicine called a placebo. A computer decides who gets which treatment by chance. Neither the doctors nor the participants will know who is taking the active drug until the trial ends. This setup helps ensure that the results are completely fair and unbiased.

Taking part in this study could help doctors better understand whether RO7568282 can slow the progression of Parkinson’s disease. Even if the medicine does not directly help every participant, the information gathered could lead to improved treatments for people diagnosed with Parkinson’s in the years ahead.

Key takeaways

  • Tests a new medicine (RO7568282) designed to slow the progression of early Parkinson's disease.
  • Open to adults aged 18 and older diagnosed with early-stage Parkinson's.
  • A dummy treatment (placebo) is used so researchers can make a fair comparison.
  • Participation lasts about two years and involves regular clinic visits and tests.
  • Taking part is completely voluntary, and you can withdraw at any time.

Who may be eligible?

This study is open to adults aged 18 and older who have been diagnosed with early-stage Parkinson’s disease. Because the trial specifically looks at the early progression of the condition, it is designed for people whose symptoms have developed relatively recently.

To be suitable, participants need to be well enough to attend regular clinic appointments and complete the study assessments. Men and women of all backgrounds are welcome to take part.

Certain people may not be able to join. For example, individuals with advanced Parkinson’s, other significant medical conditions, or those taking specific medications that could interact with the trial drug may be excluded to ensure their safety.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with early-stage Parkinson’s disease.
  3. I am able and willing to travel to regular clinic visits for about two years.
  4. I am comfortable having routine health checks like blood tests and heart scans.
  5. I am willing to take an experimental medicine or a placebo as directed.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for about two years (up to 104 weeks). During this time, you will make regular visits to a hospital clinic so the medical team can monitor your health.

At these visits, doctors will assess your movement and physical symptoms. Some checks will be done when you have temporarily paused your usual Parkinson's medication, allowing doctors to see how your body manages on its own. You will also have routine safety checks, including blood tests, urine tests, blood pressure measurements, and heart traces (ECGs).

The team will ask you questions about your mood, mental wellbeing, and daily activities. You will take either the study drug or a placebo as directed by the clinic staff, and you will have follow-up visits to track your progress throughout the trial.

Potential risks and benefits

You may or may not experience direct health benefits from taking part in this trial. While researchers hope the medicine slows down movement symptoms, there is no guarantee it will work, and you might receive the placebo instead. You will, however, receive regular, detailed health checks from specialist Parkinson's doctors. As with any new medicine, there is a risk of side effects, which the study team will explain in detail. Some visits may also feel tiring, especially when pausing your usual medicines for tests. Joining the trial is entirely your choice, and you can withdraw at any time without your regular NHS care being affected.

Locations (8)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Germany
  • —
    Unverified
    Italy
  • —
    Unverified
    Netherlands
  • —
    Unverified
    Poland
  • —
    Unverified
    France
  • —
    Unverified
    Ireland
  • —
    Unverified
    Spain
  • —
    Unverified
    Austria

Common questions

What is a placebo?

A placebo is a dummy treatment that looks just like the real medicine but contains no active ingredients. It helps doctors see if the real drug works better than no treatment at all.

Will I know if I am getting the real medicine?

No. Neither you nor your study doctor will know whether you are taking the study drug or the placebo. This ensures the results are completely unbiased.

Do I have to stop taking my regular Parkinson's medicines?

You will generally continue your routine care, but you may need to pause your usual Parkinson's medicines for short periods before specific clinic checks so doctors can measure your natural movement.

How long will I be in the trial?

The study runs for around 104 weeks, which is about two years, involving regular clinic visits and health assessments.

Can I leave the study if I change my mind?

Yes. Taking part is entirely voluntary, and you are free to leave the trial at any point without it affecting your standard medical care.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.